Looking to hold an advisory board? Here are a few suggestions.
The industry has struggled to recruit talent for years, and the challenge is only getting more difficult. Pharma companies need to recruit differently.
Learn how breakthrough patient experience strategies can help achieve your study goals in this upcoming webcast. Lead by renowned neuroscientist and behavioral economist Dr. Paul Glimcher, it’s the one webcast this year your team can’t afford to miss. Live: Tuesday, May 19, 2020 at 1pm EDT | 12pm CDT | 10am PDT On demand available after airing until May 19, 2021.
Recent increases in employee burnout and turnover must be addressed.
With increasing cases of disinformation across social media blurring the lines of what’s credible and real, how can pharma break through the noise and build back public trust?
Life sciences transformations rarely fail because of what was in the plan. They fail because of what was not. Explore five trends that will determine their success in coming years.
The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate.
Life sciences companies uniquely tasked with meeting continuous and complex compliance-reporting requirements.
COVID-19 creates a unique chance to refocus STEM strategies.
Regardless of engagement mode pursued, personalization is the key.
Fiona Huzarski outlines four key recruitment lessons that pharma can take from the coronavirus crisis and use to move forward and thrive.
The pharmaceutical industry must have crisis communications prepared now to anticipate unforeseen events—especially those that impact public trust.
A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
By using real-world data (RWD) and the insights derived from it, real-world evidence (RWE) earlier in research and development, drugmakers can make more informed decisions and reduce the financial risks that drive up drug prices.
A survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
The importance of equitable approaches to diagnosis and treatment.
The use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between AI’s potential and its full utilization in this space.
The pharma industry claims to be patient-centric, but, asks Claus Møldrup, how can this be the case if the evolving user experience isn’t always at the forefront of the industry's mind and informing decisions?
Disruptive strategies are essential to grow the pharma industry.
For many years, high energy use and its impact on the environment by businesses within the life sciences sector had been generally overlooked in national and global efforts to combat climate change. But with “carbon neutrality” the new buzzwords, how is the sector embracing this push for change?
Why tapping the value generated for the next set of therapies is critical.
A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.
Thursday, April 28, 2022 at 11am PDT | 2pm EDT Are you ready for the challenges of going public? Whether you are a fast-growing biotech company or are currently public and looking for SOX compliance, this webinar will cover how to set up scalable and compliant financial processes.
The challenges in obesity research are significant, but the opportunities for innovation are equally profound.
Key opinion leaders may not be hard to find, but they are very hard to engage because everybody wants a piece of them.
How pharma companies can reduce the risk of failure with AI-based innovations.